Intuitive launches new da Vinci 5 software features enhancing surgical efficiency with real-time insights and remote updates capabilities.
Quiver AI Summary
Intuitive, a leader in robotic-assisted surgery, announced new software features for its da Vinci 5 system aimed at improving surgical efficiency and outcomes. The da Vinci 5 boasts significantly enhanced computing power, enabling features like Force Gauge, which provides real-time visual feedback on force applied during surgery, and In-Console Video Replay, allowing surgeons to review key moments of the procedure without leaving their console. Additionally, the Network CCM feature allows for remote software updates, which could streamline administrative processes in hospitals. These advancements, informed by user feedback, are positioned to enhance surgical safety and efficacy, with early adopters like Adventist Health reporting positive outcomes. All new features have received FDA clearance, marking an ongoing commitment to innovation in minimally invasive surgery.
Potential Positives
- Intuitive has announced innovative software capabilities for the da Vinci 5, significantly enhancing surgical efficiency and patient outcomes through real-time insights.
- The da Vinci 5 boasts over 10,000 times the computing power of its predecessor, enabling advanced features such as Force Gauge and In-Console Video Replay.
- Both Force Gauge and In-Console Video Replay have received FDA 510(k) clearance, validating the technological advancements and commitment to safety and efficacy in surgical procedures.
- Network CCM allows hospitals to implement software updates remotely, streamlining operations and reducing administrative burdens for healthcare teams.
Potential Negatives
- The press release includes forward-looking statements that warn of significant risks and uncertainties, which may lead to actual results differing materially from expectations.
- The integration of new features like Force Gauge and In-Console Video Replay may raise concerns about the complexities and potential for technical issues during surgeries.
- The availability of the new software features may be limited by regulatory approvals in different markets, potentially excluding some customers from accessing these innovations.
FAQ
What are the new software features of da Vinci 5?
The new software capabilities include Force Gauge, In-Console Video Replay, and Network CCM designed to enhance surgical efficiency.
How does the Force Gauge feature work?
Force Gauge provides real-time feedback on the force applied to tissue during surgery, displayed through a visual indicator.
What benefits does In-Console Video Replay offer?
In-Console Video Replay allows surgeons to review earlier moments of a surgery without leaving the console, enhancing decision-making.
How does Network CCM improve system updates?
Network CCM enables remote processing of software updates for the da Vinci 5, reducing administrative burdens for hospital teams.
What is the significance of da Vinci 5's computing power?
Da Vinci 5 has over 10,000 times the computing power of da Vinci Xi, allowing for innovative features and improved surgical capabilities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Congressional Stock Trading
Members of Congress have traded $ISRG stock 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 07/10 and 2 sales worth up to $30,000 on 07/16, 06/09.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 1 purchase worth up to $50,000 on 05/08 and 2 sales worth up to $100,000 on 05/12, 04/07.
- REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 04/09.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- GARY S GUTHART (Executive Chair of the Board o) has made 0 purchases and 4 sales selling 40,053 shares for an estimated $19,194,645.
- AMY L LADD has made 0 purchases and 7 sales selling 9,447 shares for an estimated $4,742,258.
- MYRIAM CURET (EVP & Chief Medical Officer) has made 0 purchases and 2 sales selling 8,500 shares for an estimated $4,268,880.
- JAMI K NACHTSHEIM sold 2,400 shares for an estimated $1,248,000
- GARY LOEB (EVP & Chief Legal and Complian) sold 1,700 shares for an estimated $872,405
- MARK BROSIUS (SVP & Chief Mfg and Supply Cha) has made 0 purchases and 10 sales selling 1,184 shares for an estimated $657,803.
- ROBERT DESANTIS (EVP & Chief Strategy & Corp Op) has made 0 purchases and 6 sales selling 990 shares for an estimated $508,508.
- JAMIE SAMATH (See Remarks) sold 915 shares for an estimated $483,074
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Hedge Fund Activity
We have seen 1,212 institutional investors add shares of $ISRG stock to their portfolio, and 910 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GAMMA INVESTING LLC removed 3,021,842 shares (-99.8%) from their portfolio in Q2 2025, for an estimated $1,642,099,161
- WCM INVESTMENT MANAGEMENT, LLC removed 1,189,761 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $646,528,025
- GQG PARTNERS LLC removed 1,145,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $567,232,731
- FMR LLC removed 1,072,651 shares (-11.0%) from their portfolio in Q2 2025, for an estimated $582,889,279
- VICTORY CAPITAL MANAGEMENT INC added 943,348 shares (+219.1%) to their portfolio in Q2 2025, for an estimated $512,624,736
- JPMORGAN CHASE & CO removed 896,971 shares (-10.5%) from their portfolio in Q2 2025, for an estimated $487,423,011
- AMUNDI removed 815,166 shares (-24.7%) from their portfolio in Q2 2025, for an estimated $442,969,356
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ISRG Analyst Ratings
Wall Street analysts have issued reports on $ISRG in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 08/19/2025
- Wells Fargo issued a "Overweight" rating on 07/23/2025
- BTIG issued a "Buy" rating on 07/23/2025
- Piper Sandler issued a "Overweight" rating on 07/23/2025
- Deutsche Bank issued a "Sell" rating on 06/09/2025
- Citigroup issued a "Buy" rating on 05/22/2025
- Barclays issued a "Overweight" rating on 04/24/2025
To track analyst ratings and price targets for $ISRG, check out Quiver Quantitative's $ISRG forecast page.
$ISRG Price Targets
Multiple analysts have issued price targets for $ISRG recently. We have seen 11 analysts offer price targets for $ISRG in the last 6 months, with a median target of $595.0.
Here are some recent targets:
- Shagun Singh from RBC Capital set a target price of $615.0 on 08/19/2025
- Larry Biegelsen from Wells Fargo set a target price of $599.0 on 07/23/2025
- Ryan Zimmerman from BTIG set a target price of $571.0 on 07/23/2025
- Danielle Antalffy from UBS set a target price of $585.0 on 07/23/2025
- Adam Maeder from Piper Sandler set a target price of $595.0 on 07/23/2025
- Richard Newitter from Truist Securities set a target price of $600.0 on 07/23/2025
- Vijay Kumar from Evercore ISI Group set a target price of $550.0 on 07/08/2025
Full Release
SUNNYVALE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the first in a series of new software capabilities for da Vinci 5, designed to enhance surgeon and hospital efficiency through the delivery of a range of real-time surgical insights.
Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi. This enables innovative new system capabilities including:
- Force Gauge — a speedometer-like visual indicator that shows the force being applied at the Force Feedback instrument tip.
- In-Console Video Replay — an intraoperative feature that enables surgeons to revisit and review key moments from an ongoing procedure — without ever removing their head from the console.
-
Network CCM
— a new feature that enables hospital teams to process software updates — including Force Gauge and In-Console Video Replay — remotely.
“The expanded computing power of da Vinci 5 offers an opportunity to continuously optimize and extend platform performance capabilities through sequential software releases,” said Intuitive Chief Executive Officer Dave Rosa. “We pay careful attention to our customers’ long-term needs, and the integration of these latest features is the next step towards realizing what we set out to achieve with da Vinci 5 – helping surgeons and care teams to optimize efficiencies, deliver improved patient outcomes, and ultimately lower the total cost of care.”
Force Gauge
When using Force Feedback instruments, da Vinci 5 now displays relative real-time force applied to tissue during surgery through Force Gauge—a speedometer-like visual indicator that shows the force being applied at the Force Feedback instrument tip. Force Gauge is designed to support a greater awareness of force applied to tissue, measuring force within a 0–6.5 Newton range.
“We’ve had the opportunity to use da Vinci 5 Force Feedback technology for over a year and a half at Adventist Health Simi Valley, and we are finding that we are consistently applying less force to tissue during procedures,” said Dr. Andrea Pakula, Medical Director of Robotic Surgery at Adventist Health.
“Now, with the addition of the new Force Gauge feature, we have a real-time visual indicator of the force being applied through the instruments. This provides immediate feedback and adds another layer of information to allow us to further refine our technique. I'm excited to see how these enhancements could support gentler, safer surgery, as we remain focused on achieving the best possible outcomes for our patients.”
Recently published data in The American Journal of Surgery suggests that Force Feedback technology can reduce the total amount of force applied during surgery—without negatively impacting primary outcomes such as bowel function or length of hospital stay. 1
In-Console Video Replay
In-Console Video Replay is an intraoperative feature that enables surgeons to revisit and review video from earlier moments in the same procedure—without ever removing their head from the console. The replay appears directly in their field of view, alongside a live picture-in-picture window for continuous situational awareness.
Fully integrated into the da Vinci 5 system, In-Console Video Replay captures the entire procedure locally and temporarily, to support a surgeon’s real-time decision-making, collaborative review between dual consoles, and improved procedural safety and efficiency.
Network CCM
Force Gauge and In-Console Video Replay will be made available to customers in the U.S. through Network CCM, a real-time system update feature for da Vinci 5. With Network CCM, new software features can be enabled remotely, which could help to reduce administrative burdens by enabling hospital teams to process new software updates remotely.
The announcement of these new software capabilities for da Vinci 5 was made at Intuitive 360, an annual peer-to-peer educational forum where experiences, ideas and best practices are shared – all with the vision to provide better outcomes and equitable access to care.
Force Gauge, In-Console Video Replay and Network CCM da Vinci 5 software features have all received 510(k) clearance from the U.S. Food & Drug Administration (FDA). These updates reflect the ongoing software innovation to enhance the da Vinci 5 platform, informed by early customer feedback and supported by our long-term development strategy.
These features may not be available in all countries. Product availability is subject to regulatory approval in the specific market. Please contact your local Intuitive representative for product availability in your region.
About Intuitive
Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About da Vinci Surgical Systems
There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
For more information, please visit the company’s website at www.intuitive.com .
Important Safety Information
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit
https://manuals.intuitivesurgical.com/market
. For summary of the risks associated with surgery refer to
www.intuitive.com/safety
.
Forward-Looking Statements
This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements.
These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, integration of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals.
These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Contact Information:
Megan Elliott
[email protected]
+1 408-523-8181 ext. 6934681
1 Chang GC, Upinder S, Debra, L, Vargas G, Shah S, Rashidi L. A pilot study on the impact of da Vinci 5's force feedback on clinical outcomes: Does it lead to less tissue trauma in colorectal surgery? The American Journal of Surgery (2025). https://doi.org/10.1016/j.amjsurg.2025.116518
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/92d49977-772b-4db1-900e-9387c91f322e